Inari Medical (NARI)
(Delayed Data from NSDQ)
$44.23 USD
+0.76 (1.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $44.25 +0.02 (0.05%) 7:42 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.23 USD
+0.76 (1.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $44.25 +0.02 (0.05%) 7:42 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Zacks News
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
by Zacks Equity Research
NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall
by Zacks Equity Research
Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.
Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical (NARI) delivered earnings and revenue surprises of -156.25% and 1.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) second-quarter results are likely to reflect strong performance in the Diagnostics segment.
Lower Volume Likely to Hurt GE HealthCare's (GEHC) Q2 Earnings
by Zacks Equity Research
GE HealthCare's (GEHC) second-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line results may reflect better pricing.
Factors Setting the Tone for Ecolab's (ECL) Q2 Earnings
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Inari Medical (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2024 results are likely to reflect rising volumes across all channels.
Intuitive Surgical (ISRG) Hits All-Time High: Will It Go Higher?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported robust quarterly performance last week, and its shares touched an all-time high. Will the company's fundamentals support further upside?
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Here's Why You Should Retain Inari Medical (NARI) for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inari's (NARI) Expanding Product Portfolio Offsets Competition
by Zacks Equity Research
Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.
Inari Medical (NARI) Sues Truvic on Patent Infringement
by Zacks Equity Research
Inari Medical (NARI) files a patent infringement lawsuit against Imperative Care and its subsidiary Truvic over intentionally copying and overlapping the designs of Inari Medical's products.
Here's Why You Should Retain Inari Medical (NARI) for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises
by Zacks Equity Research
Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.
Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical (NARI) delivered earnings and revenue surprises of -136.36% and 3.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how the five medical device stocks, SYK, GEHC, ECL, NARI and MMSI, might fare in their quarterly results slated to be released tomorrow.
Why You Should Retain Inari Medical (NARI) Stock for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Inari Medical (NARI) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inari Medical (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inari Medical's (NARI) ClotTriever Improves Patient Outcome
by Zacks Equity Research
Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.